Treatment efficacy of 0.05% cyclosporine eyedrop on ocular surface changes after anti-glaucoma medication in glaucoma patients.

Keimyung University Dongsan Hospital0 个研究点目标入组 30 人开始时间: 待定最近更新: 2022年4月4日

适应症

试验速览

暂无简介。

•1) A patient with glaucoma who is 19 years of age or older and has been instilling one or more antiglaucoma eye drops bilaterally for at least one,
•2) Based on the Korean dry eye treatment guidelines at the time of first enrolling, and the diagnostic criteria presented by the Dry Eye Workshop in 2007, dry eye syndrome of level 2 or higher
•3) Patients who can be followed up for at least 4 months
•4) Patients who accurately understands the details of the clinical trial and has written a consent form from a voluntary doctor

•1) Level 1 and 2 mild dry eye syndrome patients
•2) Those who have had hypersensitivity reactions to this drug or other drugs, or those with a history of clinically significant hypersensitivity reactions
•3) Patients who are pregnant, lactating, or planning to become pregnant
•4) Those who participated in other clinical trials within 3 months before the first administration date
•5) If there is a history of corneal or glaucoma surgery or intraocular surgery within 6 months of screening
•6) Patients who want to wear contact lenses during the clinical trial period
•7) Patients with eye diseases that require treatment other than dry eye syndrome and glaucoma
•8) Patients received lacrimal punctal surgery (punctal plug and surgical lacrimal closure) within 1 month before instillation

发起方

Keimyung University Dongsan Hospital